A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance
Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic
Typ dokumentu časopisecké články
PubMed
28384387
DOI
10.1111/ejh.12894
Knihovny.cz E-zdroje
- Klíčová slova
- monoclonal gammopathy, multiple myeloma, progression, risk factors,
- MeSH
- biologické markery MeSH
- hodnocení rizik MeSH
- hybridizace in situ fluorescenční MeSH
- Kaplanův-Meierův odhad MeSH
- kostní dřeň patologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- monoklonální gamapatie nejasného významu diagnóza epidemiologie metabolismus MeSH
- myelomové proteiny metabolismus MeSH
- nádorová transformace buněk MeSH
- plazmatické buňky metabolismus patologie MeSH
- progrese nemoci MeSH
- proporcionální rizikové modely MeSH
- registrace MeSH
- rizikové faktory MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- surveillance populace MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Česká republika epidemiologie MeSH
- Názvy látek
- biologické markery MeSH
- multiple myeloma M-proteins MeSH Prohlížeč
- myelomové proteiny MeSH
INTRODUCTION: Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant condition with a risk of malignant conversion. PATIENTS AND METHODS: With the aim to estimate the cumulative risk MGUS progression to hematologic malignancies, we analyzed a nationwide population-based cohort of 1887 MGUS patients from the Czech Registry of Monoclonal Gammopathies (RMG) between 2007 and 2013. RESULTS: During the follow-up period (median 4 years; range 0.6-34.8), progression to hematologic malignancies was observed in 8.6% (162 of 1887) of patients. Factors associated with progression were as follows: M-protein concentration ≥1.5 g/dL, pathological sFLC (<0.26 or >1.65) ratio, bone marrow plasma cells (BMPCs) in cytology >5%, immunoparesis, age ≥69 years, and the level of serum hemoglobin at baseline <12.0 g/dL. Combining these factors, we propose a new risk model (CMG model). The risk of progression at 10 years was 1.6%, 16.9%, 22.9%, 39.4%, and 52.3%, respectively, if 0 (reference group), one, two, three, or four to five risk factors are present (P<.001) with HR 63 times higher compared to the reference MGUS group. CONCLUSION: The new CMG model was established with an advantage for better identification of MGUS patients at low risk.
Department of Clinical Hematology Hospital České Budejovice Czech Republic
Department of Clinical Hematology Hospital Havířov Czech Republic
Department of Clinical Hematology Hospital Liberec Czech Republic
Department of Clinical Hematology Hospital Nový Jičín Czech Republic
Department of Clinical Hematology Thomayer Hospital Praha Czech Republic
Department of Clinical Hematology University Hospital Brno Brno Czech Republic
Department of Clinical Hematology University Hospital Kralovske Vinohrady Praha Czech Republic
Department of Clinical Hematology University Hospital Ostrava Czech Republic
Department of Experimental Biology Faculty of Science Masaryk University Brno Czech Republic
Department of Hemato Oncology University Hospital Olomouc Czech Republic
Department of Hematology and Transfusion Hospital Mlada Boleslav Czech Republic
Department of Hematology and Transfusion Hospital Opava Czech Republic
Department of Hematology and Transfusion Medicine Hospital Pelhřimov Czech Republic
Department of Internal Medicine Hematology and Oncology University Hospital Brno Czech Republic
Department of Internal Medicine University Hospital Praha Czech Republic
Department of Medicine Hematology University Hospital Hradec Kralove Czech Republic
Institute of Biostatistics and Analyses Faculty of Medicine Masaryk University Brno Czech Republic
Citace poskytuje Crossref.org
